I'm LongbridgeAI, I can summarize articles.Medicus Pharma's UK subsidiary, Antev, has appointed Faisal Mehmud as CEO effective August 30, 2026. Mehmud retains his roles as Medicus chief medical officer and Antev co-chair, consolidating leadership for the Teverelix development program. He succeeds interim CEO Amit Kohli, who facilitated the transition following Medicus's acquisition deal closed on August 29, 2025.
- Medicus’ UK subsidiary Antev named Faisal Mehmud CEO, effective Aug. 30, 2026. * Mehmud keeps roles as Medicus chief medical officer, Antev co-chair, consolidating leadership for Teverelix development and regulatory work. * He replaces interim CEO Amit Kohli, who stayed one year post-acquisition to support transition following the Aug. 29, 2025 deal close. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030730PRIMZONEFULLFEED9802179) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)